Search

Your search keyword '"Chasnyk, Vyacheslav"' showing total 141 results
Start Over Author "Chasnyk, Vyacheslav" Search Limiters Full Text
141 results on '"Chasnyk, Vyacheslav"'

1. Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry

Author

van Straalen, Joeri W., Baas, Laurie, Giancane, Gabriella, Grebenkina, Lyudmila, Brunner, Jurgen, Vega-Cornejo, Gabriel, Chasnyk, Vyacheslav G., Harel, Liora, Appenzeller, Simone, Gervais, Elisabeth, de Roock, Sytze, Wulffraat, Nico M., Ruperto, Nicolino, and Swart, Joost F.

Published
2023
Full Text
View/download PDF

2. The population history of northeastern Siberia since the Pleistocene

Author

Sikora, Martin, Pitulko, Vladimir V, Sousa, Vitor C, Allentoft, Morten E, Vinner, Lasse, Rasmussen, Simon, Margaryan, Ashot, de Barros Damgaard, Peter, de la Fuente, Constanza, Renaud, Gabriel, Yang, Melinda A, Fu, Qiaomei, Dupanloup, Isabelle, Giampoudakis, Konstantinos, Nogués-Bravo, David, Rahbek, Carsten, Kroonen, Guus, Peyrot, Michaël, McColl, Hugh, Vasilyev, Sergey V, Veselovskaya, Elizaveta, Gerasimova, Margarita, Pavlova, Elena Y, Chasnyk, Vyacheslav G, Nikolskiy, Pavel A, Gromov, Andrei V, Khartanovich, Valeriy I, Moiseyev, Vyacheslav, Grebenyuk, Pavel S, Fedorchenko, Alexander Yu, Lebedintsev, Alexander I, Slobodin, Sergey B, Malyarchuk, Boris A, Martiniano, Rui, Meldgaard, Morten, Arppe, Laura, Palo, Jukka U, Sundell, Tarja, Mannermaa, Kristiina, Putkonen, Mikko, Alexandersen, Verner, Primeau, Charlotte, Baimukhanov, Nurbol, Malhi, Ripan S, Sjögren, Karl-Göran, Kristiansen, Kristian, Wessman, Anna, Sajantila, Antti, Lahr, Marta Mirazon, Durbin, Richard, Nielsen, Rasmus, Meltzer, David J, Excoffier, Laurent, and Willerslev, Eske

Subjects
Asia, DNA, Ancient, Europe, Gene Pool, Genome, Human, Haplotypes, History, 15th Century, History, Ancient, History, Medieval, Human Migration, Humans, Indians, North American, Male, Siberia, General Science & Technology
Abstract

Northeastern Siberia has been inhabited by humans for more than 40,000 years but its deep population history remains poorly understood. Here we investigate the late Pleistocene population history of northeastern Siberia through analyses of 34 newly recovered ancient genomes that date to between 31,000 and 600 years ago. We document complex population dynamics during this period, including at least three major migration events: an initial peopling by a previously unknown Palaeolithic population of 'Ancient North Siberians' who are distantly related to early West Eurasian hunter-gatherers; the arrival of East Asian-related peoples, which gave rise to 'Ancient Palaeo-Siberians' who are closely related to contemporary communities from far-northeastern Siberia (such as the Koryaks), as well as Native Americans; and a Holocene migration of other East Asian-related peoples, who we name 'Neo-Siberians', and from whom many contemporary Siberians are descended. Each of these population expansions largely replaced the earlier inhabitants, and ultimately generated the mosaic genetic make-up of contemporary peoples who inhabit a vast area across northern Eurasia and the Americas.

Published
2019

3. Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

Author

Avrusin, Ilia S., primary, Abramova, Natalia N., additional, Belozerov, Konstantin E., additional, Kondratiev, Gleb V., additional, Bregel, Liudmila V., additional, Efremova, Olesya S., additional, Vilnits, Alla A., additional, Konstantinova, Julia E., additional, Isupova, Eugenia A., additional, Kornishina, Tatiana L., additional, Masalova, Vera V., additional, Felker, Eugeniy Yu., additional, Kalashnikova, Olga V., additional, Chasnyk, Vyacheslav G., additional, Aleksandrovich, Yuriy S., additional, and Kostik, Mikhail M., additional

Published
2023
Full Text
View/download PDF

4. OA03 Are there any differences in the outcomes of treatment of a 12-month course of rituximab BCD020 biosimilar in systemic lupus erythematosus in children with early and late administration of the drug

Author

Kalashnikova, Elvira, primary, Rinat, Raupov, additional, Lubimova, Natalia, additional, Ekaterina, Kuchinskaya, additional, Isupova, Eugeniya, additional, Gaidar, Ekaterina, additional, Masalova, Vera, additional, Snegireva, Lyudmila, additional, Kornishina, Tatyana, additional, Sorokina, Lyuobov, additional, Kaneva, Mariya, additional, Kalashnikova, Olga, additional, Burtseva, Tatiana, additional, Argunova, Vera, additional, Sleptsova, Polina, additional, Chasnyk, Vyacheslav, additional, and Kostik, Mikhail, additional

Published
2023
Full Text
View/download PDF

5. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Author

Foeldvari, Ivan, Constantin, Tamàs, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Dobrzyniecka, Bogna, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald D., Bukowski, Jack F., Vlahos, Bonnie, Martini, Alberto, Ruperto, Nicolino, and for the Paediatric Rheumatology International Trials Organisation (PRINTO)

Published
2019
Full Text
View/download PDF

6. Using HScore for Evaluation of Hemophagocytosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children.

Author

Avrusin, Ilia S., Abramova, Natalia N., Belozerov, Konstantin E., Bregel, Liudmila V., Efremova, Olesya S., Vilnits, Alla A., Konstantinova, Julia E., Isupova, Eugenia A., Kornishina, Tatiana L., Masalova, Vera V., Kalashnikova, Olga V., Chasnyk, Vyacheslav G., Aleksandrovich, Yuriy S., Ivanov, Dmitri O., and Kostik, Mikhail M.

Subjects
MULTISYSTEM inflammatory syndrome, BLOOD sedimentation, MULTISYSTEM inflammatory syndrome in children, ASPIRIN, COVID-19, HAND-foot syndrome, MYELOFIBROSIS
Abstract

Hemophagocytic syndrome is a key point in the pathogenesis of severe forms of multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C). The factors associated with hemophagocytosis in patients with MIS-C were assessed in the present study of 94 boys and 64 girls ranging in age from 4 months to 17 years, each of whose HScore was calculated. In accordance with a previous analysis, patients with HScore ≤ 91 (n = 79) and HScore > 91 (n = 79) were compared. Patients with HScore > 91 had a higher frequency of symptoms such as cervical lymphadenopathy, dry cracked lips, bright mucous, erythema/swelling of hands and feet, peeling of fingers, edematous syndrome, hepatomegaly, splenomegaly, and hypotension/shock. They also had a higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and D-dimer levels, and a tendency to anemia, thrombocytopenia, and hypofibrinogenemia. They more often needed acetylsalicylic acid and biological treatment and were admitted to ICU in 70.9% of cases. Conclusion: The following signs of severe MIS-C were associated with HScore > 91: myocardial involvement, pericarditis, hypotension/shock, and ICU admission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study

Author

Kostik, Mikhail, primary, Kalashnikova, Elvira, additional, Rinat, Raupov, additional, Isupova, Eugenia, additional, Gaidar, Ekaterina, additional, Soloviev, Anton A., additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, Kornishina, Tatyana, additional, Abramova, Natalia, additional, Suspitsin, Evgeny, additional, Sorokina, Lubov, additional, Kaneva, Maria, additional, Dubko, Margarita F., additional, Lubimova, Natalia, additional, Kuchuinskaya, Ekaterina, additional, Kalashnikova, Olga, additional, and Chasnyk, Vyacheslav, additional

Published
2023
Full Text
View/download PDF

8. COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report

Author

Belozerov, Konstantin E., primary, Avrusin, Ilia S., additional, Andaryanova, Lyubov I., additional, Guseva, Anna M., additional, Shogenova, Zaira S., additional, Belanovich, Irina N., additional, Lobacheva, Anna V., additional, Kornishina, Tatiana L., additional, Isupova, Eugenia A., additional, Masalova, Vera V., additional, Kalashnikova, Olga V., additional, Nokhrin, Andrey V., additional, Panova, Tatyana F., additional, Dutova, Yulia P., additional, Myshkovskaya, Svetlana L., additional, Kostyunin, Kirill Y., additional, Komissarov, Andrey B., additional, Chasnyk, Vyacheslav G., additional, Bregel, Liudmila V., additional, and Kostik, Mikhail M., additional

Published
2023
Full Text
View/download PDF

9. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

Author

Kostik, Mikhail M., primary, Isupova, Eugenia A., additional, Belozerov, Konstantin, additional, Likhacheva, Tatyana S., additional, Suspitsin, Evgeny N., additional, Raupov, Rinat, additional, Masalova, Vera V., additional, Chikova, Irina A., additional, Dubko, Margarita F., additional, Kalashnikova, Olga V., additional, Chasnyk, Vyacheslav G., additional, and Cron, Randy Q., additional

Published
2022
Full Text
View/download PDF

10. Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics

Author

Kostik, Mikhail M., primary, Gaidar, Ekaterina V., additional, Sorokina, Lubov S., additional, Avrusin, Ilya S., additional, Nikitina, Tatiana N., additional, Isupova, Eugenia A., additional, Chikova, Irina A., additional, Korin, Yuri Yu., additional, Orlova, Elizaveta D., additional, Snegireva, Ludmila S., additional, Masalova, Vera V., additional, Dubko, Margarita F., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2022
Full Text
View/download PDF

11. OA37 Secukinumab treatment in children and adolescents with enthesitis-related arthritis and juvenile psoriatic arthritis: efficacy and safety results from a Phase 3 study

Author

Ramanan, Athimalaipet V, primary, Brunner, Hermine I, additional, Foeldvari, Ivan, additional, Alexeeva, Ekaterina, additional, Ayaz, Nuray A, additional, Calvo, Inmaculada, additional, Kasapcopur, Ozgur, additional, Chasnyk, Vyacheslav G, additional, Hufnagel, Markus, additional, Zuber, Zbigniew, additional, Schulert, Grant, additional, Ozen, Seza, additional, Popov, Artem, additional, Scott, Christiaan, additional, Sözeri, Betul, additional, Zholobova, Elena, additional, Zhu, Xuan, additional, Whelan, Sarah, additional, Pricop, Luminita, additional, Ravelli, Angelo, additional, Martini, Alberto, additional, Lovell, Daniel J, additional, and Ruperto, Nicolino, additional

Published
2022
Full Text
View/download PDF

12. Heart Involvement in Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children: The Retrospective Multicenter Cohort Data

Author

Kostik, Mikhail M., primary, Bregel, Liudmila V., additional, Avrusin, Ilia S., additional, Efremova, Olesya S., additional, Belozerov, Konstantin E., additional, Dondurei, Elena A., additional, Kornishina, Tatiana L., additional, Isupova, Eugenia A., additional, Abramova, Natalia N., additional, Felker, Eugeniy Yu, additional, Masalova, Vera V., additional, Santimov, Andrey V., additional, Kozlov, Yuri A., additional, Barakin, Alexander O., additional, Snegireva, Ludmila S., additional, Konstantinova, Julia, additional, Vilnits, Alla A., additional, Bekhtereva, Maria K., additional, Argunova, Vera M., additional, Matyunova, Alla E., additional, Sleptsova, Polina A., additional, Burtseva, Tatyana E., additional, Shprakh, Vladimir V., additional, Boyko, Tatyana V., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2022
Full Text
View/download PDF

13. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

Author

Ravelli, Angelo, Minoia, Francesca, Davì, Sergio, Horne, AnnaCarin, Bovis, Francesca, Pistorio, Angela, Aricò, Maurizio, Avcin, Tadej, Behrens, Edward M., De Benedetti, Fabrizio, Filipovic, Lisa, Grom, Alexei A., Henter, Jan-Inge, Ilowite, Norman T., Jordan, Michael B., Khubchandani, Raju, Kitoh, Toshiyuki, Lehmberg, Kai, Lovell, Daniel J., Miettunen, Paivi, Nichols, Kim E., Ozen, Seza, Schmid, Jana Pachlopnik, Ramanan, Athimalaipet V., Russo, Ricardo, Schneider, Rayfel, Sterba, Gary, Uziel, Yosef, Wallace, Carol, Wouters, Carine, Wulffraat, Nico, Demirkaya, Erkan, Brunner, Hermine I., Martini, Alberto, Ruperto, Nicolino, Cron, Randy Q., Abinun, Mario, Aggarwal, Amita, Akikusa, Jonathan, Al-Mayouf, Sulaiman M., Alessio, Maria, Anton, Jordi, Apaz, Maria Teresa, Astigarraga, Itziar, Ayaz, Nuray A., Barone, Patrizia, Bica, Blanca, Bolt, Isabel, Breda, Luciana, Chasnyk, Vyacheslav, Cimaz, Rolando, Corona, Fabrizia, Cuttica, Ruben, DʼAngelo, Gianfranco, Davidsone, Zane, De Cunto, Carmen, De Inocencio, Jaime, Eisenstein, Eli, Enciso, Sandra, Espada, Graciela, Fischbach, Michel, Frosch, Michael, Gallizzi, Romina, Gamir, Maria Luz, Gao, Yi-Jin, Griffin, Thomas, Hashad, Soad, Hennon, Teresa, Horneff, Gerd, Huasong, Zeng, Huber, Adam, Ilowite, Norman, Insalaco, Antonella, Ioseliani, Maka, Jelusic-Drazic, Marijia, Jeng, Michael, Kapovic, Agneza, Kasapcopur, Ozgur, Kone-Paut, Isabelle, de Oliveira, Sheila Knupp Feitosa, Lattanzi, Bianca, Lepore, Loredana, Li, Caifeng, Lipton, Jeffrey M., Magni-Manzoni, Silvia, Maritsi, Despoina, McCurdy, Deborah, Merino, Rosa, Mulaosmanovic, Velma, Nielsen, Susan, Pal, Priyankar, Prahalad, Sampath, Rigante, Donato, Rumba-Rozenfelde, Ingrida, Magalhaes, Claudia Saad, Sanner, Helga, Sawhney, Sujata, Sewairi, Wafaa M., Shakoory, Bita, Shenoi, Susan, Clovis, Artur Silva, Stanevicha, Valda, Stine, Kimo C., Susic, Gordana, Sztajnbok, Flavio, Takei, Syuji, Tezer, Hasan, Trauzeddel, Ralf, Tsitsami, Elena, Unsal, Erbil, Vougiouka, Olga, Weaver, Lehn K., Weiss, Jennifer, Weitzman, Sheila, and Zletni, Mabruka

Published
2016
Full Text
View/download PDF

14. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience

Author

Kostik, Mikhail M., primary, Raupov, Rinat K., additional, Suspitsin, Evgeny N., additional, Isupova, Eugenia A., additional, Gaidar, Ekaterina V., additional, Gabrusskaya, Tatyana V., additional, Kaneva, Maria A., additional, Snegireva, Ludmila S., additional, Likhacheva, Tatyana S., additional, Miulkidzhan, Rimma S., additional, Kosmin, Artem V., additional, Tumakova, Anastasia V., additional, Masalova, Vera V., additional, Dubko, Margarita F., additional, Kalashnikova, Olga V., additional, Aksentijevich, Ivona, additional, and Chasnyk, Vyacheslav G., additional

Published
2022
Full Text
View/download PDF

15. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

Author

Grom, Alexei A., Ilowite, Norman T., Pascual, Virginia, Brunner, Hermine I., Martini, Alberto, Lovell, Daniel, Ruperto, Nicolino, Leon, Karolynn, Lheritier, Karine, Abrams, Ken, Cuttica, Ruben, Emminger, Wolfgang, Goffin, Laurence, Joos, Rik, Lauwerys, Bernard, Wouters, Carine, Hilário, Maria Odete Esteves, de Oliveira, Sheila Knupp Feitosa, Len, Claudio, Radominski, Sebastiao, Sztajnbok, Flavio Roberto, Haddad, Elie, Hofer, Michael, Houghton, Kristin, Huber, Adam, Saurenmann, Traudel, Schneider, Rayfel, Tucker, Lori, Bader-Meunier, Brigitte, Desjonqueres, Marine, Fischbach, Michel, Kone-Paut, Isabelle, Marie, Isabelle, Mogenet, Agnes, Mouy, Richard, Quartier, Pierre, Berner, Reinhard, Foeldvari, Ivan, Foell, Dirk, Frosch, Michael, Haas, Johannes-Peter, Horneff, Gerd, Hufnagel, Markus, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Lehmann, Hartwig, Lutz, Thomas, Thon, Angelika, Trauzeddel, Ralf, Tzaribachev, Nikolay, Weibarth-Riedel, Elisabeth, Chrousos, Georgios, Trachana, Maria, Vougiouka, Olga, Constantin, Tamas, Barash, Judith, Berkun, Yackov, Brik, Riva, Harel, Liora, Nahum, Amit, Pade, Shay, Uziel, Yosef, Alessio, Maria, Cimaz, Rolando, Corona, Fabrizia, Gerloni, Valeria, Wulffraat, N. M., Ferrandiz, Manuel, Rutkowska-Sak, Lidia, Alekseeva, Ekaterina, Chasnyk, Vyacheslav, Nasonov, Evgeny, Stanislav, Marina, Anton, Jordi, Calvo, Inmaculada, Gamir, Mari Luz, Robledillos, Juan Carlos, Magnusson, Bo, Erguven, Muferet, Kasapcopur, Ozgur, Ozdogan, Huri, Ozen, Seza, Unsal, Erbil, Chieng, Alice, Foster, Helen, McCann, Liza, Ramanan, Athimalaip, Southwood, Taunton, Wilkinson, Nicholas, Woo, Patricia, Higgins, Gloria Christine, Kingsbury, Daniel, Lopez-Benitez, Jorge, Marzan, Katherine, Morris, Paula, Natter, Marc, and Schikler, Kenneth Noel

Published
2016
Full Text
View/download PDF

16. Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study

Author

Kostik, Mikhail M., primary, Bregel, Liudmila V., additional, Avrusin, Ilia S., additional, Dondurei, Elena A., additional, Matyunova, Alla E., additional, Efremova, Olesya S., additional, Isupova, Eugenia A., additional, Kornishina, Tatiana L., additional, Masalova, Vera V., additional, Snegireva, Ludmila S., additional, Shprakh, Vladimir V., additional, Kozlov, Yuri A., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2021
Full Text
View/download PDF

17. Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients

Author

Minoia, Francesca, Davì, Sergio, Horne, AnnaCarin, Demirkaya, Erkan, Bovis, Francesca, Li, Caifeng, Lehmberg, Kai, Weitzman, Sheila, Insalaco, Antonella, Wouters, Carine, Shenoi, Susan, Espada, Graciela, Ozen, Seza, Anton, Jordi, Khubchandani, Raju, Russo, Ricardo, Pal, Priyankar, Kasapcopur, Ozgur, Miettunen, Paivi, Maritsi, Despoina, Merino, Rosa, Shakoory, Bita, Alessio, Maria, Chasnyk, Vyacheslav, Sanner, Helga, Gao, Yi-Jin, Huasong, Zeng, Kitoh, Toshiyuki, Avcin, Tadej, Fischbach, Michel, Frosch, Michael, Grom, Alexei, Huber, Adam, Jelusic, Marija, Sawhney, Sujata, Uziel, Yosef, Ruperto, Nicolino, Martini, Alberto, Cron, Randy Q., and Ravelli, Angelo

Published
2014
Full Text
View/download PDF

19. Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial.: 1597

Author

Brunner, Hermine, Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Cuttica, Ruben J., Keltsev, Vladimir, Xavier, Ricardo, Penades, Inmaculada Calvo, Nikishina, Irina, Rubio-Perez, Nadina, Alekseeva, Ekaterina, Chasnyk, Vyacheslav, Chavez, Jose, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl D., Spindler, Alberto, Lovell, D. J., Martini, Alberto, and De Benedetti, Fabrizio

Published
2012

20. Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part three

Author

Atsali, Erato, Kassara, Dimitra, Katsimbri, Pelagia, Boiu, Sorina, Boumpas, Dimitrios T., Papaevangelou, Vana, Oshlyanska, Olena A., Omelchenko, Ludmila I., Ljudvik, Tatiana A., Bouchalova, Katerina, Schüller, Marcel, Franova, Jana, Skotakova, Jarmila, Macku, Marie, Fellas, Antoni, Hawke, Fiona, Santos, Derek, Coda, Andrea, Kelempisioti, Anthi, Keskitalo, Paula, Glumoff, Virpi, Kulmala, Petri, Vahasalo, Paula, Mozaffar, Mohammed A., Turkistani, Asraa K., Sangoof, Samaa O., Sevostyanov, Vladislav, Zholobova, Elena, Bountouvi, Evangelia, Theodoropoulos, konstantinos, Moutsiou, Renata, Tsalapaki, Christina, Diaz, Talia, Osorio, Sofia, Braña, Maria Teresa, Ramirez, Yuridiana, Aparicio, Luis, Rodriguez, Andres, Faugier, Enrique, Maldonado, Rocio, Gicchino, Maria Francesca, Granato, Carmela, Macchini, Giulia, Capalbo, Daniela, Olivieri, Alma Nunzia, Hasson, Nathan, Marino, Achille, Narula, Sona, Lerman, Melissa, Calonge, Maria Amelia Muñoz, Loza, Sara Maria Murias, Alcobendas, Rosa Maria, Remesal, Agustin, Núñez-Cuadros, Esmeralda, Zavala, Rocio Galindo, Rego, Gisela Díaz-Cordovés, Fernández, Cristina Antúnez, Molina, Yaiza García, Cardona, Antonio L. Urda, Sahin, Nihal, Durmus, Habibe S., Pinarbasi, Ayse S., Gunduz, Zubeyde, Poyrazoglu, Muammer H., Karaman, Zehra F., Oktem, Turhan, Oner, Mithat, Dusunsel, Ruhan, Susic, Gordana, Krstajic, Tamara, Vujovic, Dragana, Radlovic, Nedeljko, Lekovic, Zoran, Novakovic, Dusica, Lomic, Gordana Milosevski, Mördrup, Karina, Hesselstrand, Gunilla, Sorić, Iva, Lamot, Lovro, Vidovic, Mandica, Lamot, Mirta, Harjacek, Miroslav, Adank, Eva, Schneider, Elvira Cannizzaro, Abdalla, Eiman, Ullah, Irfan, Jeyaseelan, L., Abdwani, Reem, Shaqsi, Laila A. L., Zakwani, Ibrahim A. l., Fanouriakis, Antonis, Janarthanan, Mahesh, Vetrichelvan, Dhanarathnamoorthy, Ramachandran, P., Geminiganesan, Sangeetha, Kumar, Dinesh, Rao, Subba, Papatesta, Eleni-Maria, Maritsi, Despoina, Eleftheriou, Irini, Tsolia, Maria, Vougiouka, Olga, Çakan, Mustafa, Ayaz, Nuray Aktay, Karadağ, Şerife Gül, Keskindemirci, Gonca, Keltsev, Vladimir, Grebenkina, Lyudmila, Kim, Kwang Nam, Ahn, Jong Gyun, Kim, Young Dae, Maggio, Maria Cristina, Cimaz, Rolando, Failla, Maria Concetta, Dones, Piera, Collura, Mirella, Corsello, Giovanni, Rhim, Jung-Woo, Kim, Ki-Hwan, Lee, Soo-Young, Han, Seung-Beom, Kang, Jin-Han, Chung, Jae-Hee, Lee, Soo-Jung, Jeong, Dae-Chul, Santimov, Andrei, Rupp, Regina, Alekseev, Igor, Plutova, Natalya, Moskvina, Ekaterina, Kruchina, Marina, Tarasenko, Aleksandra, Sokolova, Natalya, Saveleva, Ekaterina, Bogdanov, Ilia, Ivanov, Dmitrii, Kandrina, Tatiana, Kopanevich, Olga, Grafskaia, Anastasiia, Ignateva, Natalia, Pulukchu, Daria, Pavlova, Natalia, Kalashnikova, Olga, Kornishina, Tatiana, Dubko, Margarita, Chasnyk, Vyacheslav, Kostik, Mikhail, Sowdagar, Shama, Sankar, Janani, Ramesh, Venkateswari, Szabo, Iulia E., Sirbe, Claudia, Pamfil, Cristina, Damian, Laura, Rednic, Simona, Deac, Maria, Sparchez, Mihaela, Filipescu, Ileana, Parvu, Mirela, Balint, Dumitrita, and Nicoara, Ancuta

Subjects
lcsh:Diseases of the musculoskeletal system, lcsh:RJ1-570, lcsh:Pediatrics, lcsh:RC925-935, Meeting Abstracts
Published
2017
Full Text
View/download PDF

21. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study

Author

Brunner, I, Hermine Quartier, Pierre Alexeeva, Ekaterina and Constantin, Tamas Kone-Paut, Isabelle Marzan, Katherine and Schneider, Rayfel Wulffraat, Nico M. Chasnyk, Vyacheslav and Tirosh, Irit Kallinich, Tilmann Kuemmerle-Deschner, Jasmin and Wouters, Carine Lauwerys, Bernard Nikishina, Irina Trachana, Maria Vougiouka, Olga Martini, Alberto Lovell, Daniel J. and Levy, Jeremy Vritzali, Eleni Ruperto, Nicolino Paediat Rheumatology Int Trials Or

Abstract

Objective To evaluate the long-term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. Methods At enrollment, patients with active systemic JIA (ages 2 to

Published
2020

22. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Brunner, Hermine I, Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné-Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M, Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J, Levy, Jeremy, Vritzali, Eleni, Ruperto, Nicolino, Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Brunner, Hermine I, Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné-Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M, Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J, Levy, Jeremy, Vritzali, Eleni, Ruperto, Nicolino, and Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group

Abstract

OBJECTIVE: To evaluate the long-term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. METHODS: At enrollment, patients with active systemic JIA (ages 2 to <20 years) started open-label canakinumab (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included the adapted American College of Rheumatology (ACR) Pediatric 50/70/90 criteria, the Juvenile Arthritis Disease Activity Score (JADAS), and clinically inactive disease and clinical remission on medication, evaluated by either the JADAS or ACR criteria. RESULTS: Of the 123 patients (70 with fever and 52 without fever [fever status was not reported for 1 patient]), 84 (68.3%) completed the study (median duration 1.8 years). Comparable efficacy (adapted ACR Pediatric 50/70/90/100) was observed by day 15 in both subgroups (60.0%/48.6%/37.1%/24.3% in those with fever and 67.3%/48.1%/34.6%/19.2% in those without fever), and further increased thereafter. By month 6, clinical remission according to the JADAS or the ACR criteria was achieved in 17 (24.3%) and 26 (37.1%), respectively, of patients with fever and 9 (17.3%) and 12 (23.1%), respectively, of patients without fever. Median time to onset of clinical remission according to the JADAS or ACR criteria was 57 and 30 days, respectively, in those with fever, and 58 and 142 days, respectively, in those without fever. An adapted ACR Pediatric 50 response by day 15 was the strongest predictor of achieving clinical remission according to the JADAS (odds ratio [OR] 13 [95% confidence interval (95% CI) 4, 42]; P < 0.0001) or glucocorticoid discontinuation (OR 19 [95% CI 3, 114]; P = 0.002). Of the 71 of 123 patients (57.7%) who received glucocorticoids at study entry, 27 (38.0%) discontinued glucocorticoids and 21 (29.6%) reached a dose of <0.2 mg/kg/day, with no difference between those with and those without fever; 13 patients (10.6%) toler

Published
2020

23. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee

Author

Immuno/reuma patientenzorg, Child Health, Infectieziekten patientenzorg, Infection & Immunity, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Regenerative Medicine and Stem Cells, Onderzoek, Giancane, Gabriella, Swart, Joost F., Castagnola, Elio, Groll, Andreas H., Horneff, Gerd, Huppertz, Hans Iko, Lovell, Daniel J., Wolfs, Tom, Herlin, Troels, Dolezalova, Pavla, Sanner, Helga, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tamas, Vargova, Veronika, Sawhney, Sujata, Rygg, Marite, Oliveira, Sheila K., Cattalini, Marco, Bovis, Francesca, Bagnasco, Francesca, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Cuttica, Ruben, Garay, Stella Maris, Brunner, Jurgen, Emminger, Wolfgang, Appenzeller, Simone, Len, Claudio, Saad Magalhaes, Claudia, Telcharova-Mihaylovska, Albena, Harjacek, Miroslav, Jelusic, Marija, Estmann, Anne, Nielsen, Susan, Herrera Mora, Cristina, Gervais, Elisabeth, Koné-Paut, Isabelle, Quartier, Pierre, Foeldvari, Ivan, Lutz, Thomas, Minden, Kirsten, Tzaribachev, Nikolay, Trachana, Maria, Tsitsami, Elena, Vougiouka, Olga, Orban, Ilonka, Harel, Liora, Hashkes, Philip, Uziel, Yosef, Cimaz, Rolando, Civino, Adele, Consolini, Rita, D'Angelo, Gianfranco, De Benedetti, Fabrizio, Filocamo, Giovanni, Fueri, Elena, Gallizzi, Romina, Maggio, Maria Cristina, Magnolia, Maria Greca, Miniaci, Angela, Montin, Davide, Olivieri, Alma Nunzia, Pastore, Serena, Rigante, Donato, Zulian, Francesco, Rumba-Rozenfelde, Ingrida, Stanevicha, Valda, Panaviene, Violeta, Rodriguez Lozano, Ana Luisa, Rubio-Perez, Nadina, Vega Cornejo, Gabriel, Hoppenreijs, Esther, Kamphuis, Sylvia, Flato, Berit, Nordal, Ellen Berit, Abdwani, Reem, Miraval, Tatiana, Paz Gastanaga, Maria Eliana, Smolewska, Elzbieta, Ailioaie, Constantin, Cochino, Alexis Virgil, Laday, Matilda, Lazar, Calin, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Keltsev, Vladimir, Suwairi, Wafaa Mohammed Saad, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Arkachaisri, Thaschawee, Koskova, Elena, Avcin, Tadej, Ally, Mahmood, Van Rensburg, Christa Janse, Louw, Ingrid, Lopez, Jordi Anton, Boteanu, Alina Lucica, Calvo Penades, Inmaculada, De Inocencio, Jaime, Mesa-Del-Castillo, Pablo, Moreno, Estefania, Remesal, Agustin, Hofer, Michael, Gok, Faysal, Ozen, Seza, Ramanan, Athimalaipet, Pallotti, Chiara, Villa, Luca, Immuno/reuma patientenzorg, Child Health, Infectieziekten patientenzorg, Infection & Immunity, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Regenerative Medicine and Stem Cells, Onderzoek, Giancane, Gabriella, Swart, Joost F., Castagnola, Elio, Groll, Andreas H., Horneff, Gerd, Huppertz, Hans Iko, Lovell, Daniel J., Wolfs, Tom, Herlin, Troels, Dolezalova, Pavla, Sanner, Helga, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tamas, Vargova, Veronika, Sawhney, Sujata, Rygg, Marite, Oliveira, Sheila K., Cattalini, Marco, Bovis, Francesca, Bagnasco, Francesca, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Cuttica, Ruben, Garay, Stella Maris, Brunner, Jurgen, Emminger, Wolfgang, Appenzeller, Simone, Len, Claudio, Saad Magalhaes, Claudia, Telcharova-Mihaylovska, Albena, Harjacek, Miroslav, Jelusic, Marija, Estmann, Anne, Nielsen, Susan, Herrera Mora, Cristina, Gervais, Elisabeth, Koné-Paut, Isabelle, Quartier, Pierre, Foeldvari, Ivan, Lutz, Thomas, Minden, Kirsten, Tzaribachev, Nikolay, Trachana, Maria, Tsitsami, Elena, Vougiouka, Olga, Orban, Ilonka, Harel, Liora, Hashkes, Philip, Uziel, Yosef, Cimaz, Rolando, Civino, Adele, Consolini, Rita, D'Angelo, Gianfranco, De Benedetti, Fabrizio, Filocamo, Giovanni, Fueri, Elena, Gallizzi, Romina, Maggio, Maria Cristina, Magnolia, Maria Greca, Miniaci, Angela, Montin, Davide, Olivieri, Alma Nunzia, Pastore, Serena, Rigante, Donato, Zulian, Francesco, Rumba-Rozenfelde, Ingrida, Stanevicha, Valda, Panaviene, Violeta, Rodriguez Lozano, Ana Luisa, Rubio-Perez, Nadina, Vega Cornejo, Gabriel, Hoppenreijs, Esther, Kamphuis, Sylvia, Flato, Berit, Nordal, Ellen Berit, Abdwani, Reem, Miraval, Tatiana, Paz Gastanaga, Maria Eliana, Smolewska, Elzbieta, Ailioaie, Constantin, Cochino, Alexis Virgil, Laday, Matilda, Lazar, Calin, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Keltsev, Vladimir, Suwairi, Wafaa Mohammed Saad, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Arkachaisri, Thaschawee, Koskova, Elena, Avcin, Tadej, Ally, Mahmood, Van Rensburg, Christa Janse, Louw, Ingrid, Lopez, Jordi Anton, Boteanu, Alina Lucica, Calvo Penades, Inmaculada, De Inocencio, Jaime, Mesa-Del-Castillo, Pablo, Moreno, Estefania, Remesal, Agustin, Hofer, Michael, Gok, Faysal, Ozen, Seza, Ramanan, Athimalaipet, Pallotti, Chiara, and Villa, Luca

Published
2020

24. Additional file 1: of Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Author

Foeldvari, Ivan, Tamàs Constantin, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Bogna Dobrzyniecka, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald, Bukowski, Jack, Vlahos, Bonnie, Martini, Alberto, and Ruperto, Nicolino

Abstract

Table S1. Summary of missing data imputation methods for the responder analysis. Table S2. Disease activity and patient-reported outcomes (observed cases). Table S3. Outcomes specific for enthesitis-related arthritis and psoriatic arthritis (observed cases). Table S4. The most frequent TEAEs, excluding infections and injection site reactions (> 5% in any JIA subtype, by System Organ Class). Figure S1. ACR30–100 and JIA inactive disease response rates (OC vs NRI). Additional Tables (A1 to A4) and Figure A1 related to missing data imputation based on patients’ enrolment status, trial period at cut-off date, and reasons for permanent discontinuation. (DOCX 224 kb)

Published
2019
Full Text
View/download PDF

25. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis

Author

Pardeo, Manuela, Wang, Jianmei, Ruperto, Nicolino, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Schneider, Rayfel, Horneff, Gerd, Huppertz, Hans-Iko, Minden, Kirsten, Onel, Karen, Zemel, Lawrence, Martin, Alan, Kone-Paut, Isabelle, Siamopoulou-Mavridou, Antigoni, Silva, Clovis A., Porter-Brown, Benjamin, Bharucha, Kamal N., Brunner, Hermine, I, De Benedetti, Fabrizio, Pardeo, Manuela, Wang, Jianmei, Ruperto, Nicolino, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Schneider, Rayfel, Horneff, Gerd, Huppertz, Hans-Iko, Minden, Kirsten, Onel, Karen, Zemel, Lawrence, Martin, Alan, Kone-Paut, Isabelle, Siamopoulou-Mavridou, Antigoni, Silva, Clovis A., Porter-Brown, Benjamin, Bharucha, Kamal N., Brunner, Hermine, I, and De Benedetti, Fabrizio

Abstract

Objective. To determine whether neutropenia is associated with increased risk for infection in patients with systemic juvenile idiopathic arthritis (sJIA) and polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ). Methods. Data up to Week 104 from 2 phase III trials of intravenous TCZ in sJIA (n = 112; ClinicalTrials.gov, NCT00642460) and pcJIA (n = 188; ClinicalTrials.gov, NCT00988221) were pooled. Worst common toxicity criteria grade and lowest observed absolute neutrophil count (ANC) were identified for each patient. Associations between patient characteristics and lowest observed ANC were tested using univariate regression analysis. Infection and serious infection rates per 100 patient-years (PY) in periods associated with grades 1/2 and 3/4 neutrophil counts were compared with rates associated with normal neutrophil counts. Results. ANC decreased to grade >= 3 in 25.0% and 5.9% of sJIA and pcJIA patients, respectively, and decreases were transient. Young age (p = 0.047) and methotrexate use (p = 0.012) were positively associated with neutropenia in patients with sJIA but not in patients with pcJIA. The rate of serious infections in patients with sJIA (10.9/100 PY; 95% CI 6.8-165) tended to be higher than in patients with pcJIA (5.2/100 PY; 95% CI 3-8.5). No increase in rates of serious or nonserious infections was observed during periods of neutropenia in either trial. Conclusion. Patients with JIA treated with TCZ experienced transient neutropenia that was not associated with an increased number of infections.

Published
2019

26. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Author

Immunologie/Reumatologie, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Onderzoek, Child Health, Regenerative Medicine and Stem Cells, Infection & Immunity, Foeldvari, Ivan, Constantin, Tamàs, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Dobrzyniecka, Bogna, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald D., Bukowski, Jack F., Vlahos, Bonnie, Martini, Alberto, Ruperto, Nicolino, Immunologie/Reumatologie, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Onderzoek, Child Health, Regenerative Medicine and Stem Cells, Infection & Immunity, Foeldvari, Ivan, Constantin, Tamàs, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Dobrzyniecka, Bogna, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald D., Bukowski, Jack F., Vlahos, Bonnie, Martini, Alberto, and Ruperto, Nicolino

Published
2019

27. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis : results of a multicentre, double-blind, randomised-withdrawal trial

Author

Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G., Panaviene, Violeta Vladislava, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J., Del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D., Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R., Sztajnbok, Flavio, Gilmer, Keith E., Xu, Zhenhua, Leu, Jocelyn H., Kim, Lilianne, Lamberth, Sarah L., Loza, Matthew J., Lovell, Daniel J., Martini, Alberto, and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

Subjects
Rheumatology, anti-tumour necrosis factor, Biochemistry, Genetics and Molecular Biology(all), Immunology, juvenile idiopathic arthritis, Immunology and Allergy, biologics, golimumab
Abstract

OBJECTIVE: This report aims to determine the safety, pharmacokinetics (PK) and efficacy of subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA). METHODS: In this three-part randomised double-blinded placebo-controlled withdrawal trial, all patients received open-label golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks together with weekly methotrexate during Part 1 (weeks 0-16). Patients with at least 30% improvement per American College of Rheumatology Criteria for JIA (JIA ACR30) in Part 1 entered the double-blinded Part 2 (weeks 16-48) after 1:1 randomisation to continue golimumab or start placebo. In Part 3, golimumab was continued or could be restarted as in Part 1. The primary outcome was JIA flares in Part 2; secondary outcomes included JIA ACR50/70/90 responses, clinical remission, PK and safety. RESULTS: Among 173 patients with polyJIA enrolled, 89.0% (154/173) had a JIA ACR30 response and 79.2%/65.9%/36.4% demonstrated JIA ACR50/70/90 responses in Part 1. At week 48, the primary endpoint was not met as treatment groups had comparable JIA flare rates (golimumab vs placebo: 32/78=41% vs 36/76=47%; p=0.41), and rates of clinical remission were comparable (golimumab vs placebo: 10/78=12.8% vs 9/76=11.8%). Adverse event and serious adverse event rates were similar in the treatment groups during Part 2. Injection site reactions occurred with

Published
2018

28. Higher-dose canakinumab therapy for refractory macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: two case reports

Author

Chasnyk Vyacheslav Grigoryevich, Abramova Natal’Ya Nikolaevna, Chikova Irina Aleksandrovna, Buchinskaya Natal’Ya Valer’Yevna, Kostik Mikhail Mikhaylovich, Cron Randy Q, Likhacheva Tatyana Serafimovna, and Kalashnikova Olga Valeryevna

Subjects
musculoskeletal diseases, Cytopenia, Anakinra, business.industry, medicine.medical_treatment, Arthritis, medicine.disease, Canakinumab, Cytokine, Macrophage activation syndrome, Immunology, СИНДРОМ АКТИВАЦИИ МАКРОФАГОВ,MACROPHAGE ACTIVATION SYNDROME,СИСТЕМНЫЙ ЮВЕНИЛЬНЫЙ ИДИОПАТИЧЕСКИЙ АРТРИТ,SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS,ИНТЕРЛЕЙКИН-1,INTERLEUKIN-1,ANTI-IL-1 TREATMENT,КАНАКИНУМАБ,CANAKINUMAB,МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА,MONOCLONAL ANTIBODY,ТЕРАПИЯ БЛОКАТОРАМИ ИЛ-1, Medicine, Dosing, business, Adverse effect, medicine.drug
Abstract

Macrophage activation syndrome (MAS) is a life-threatening, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA) appears in non-remitted fever, cytopenia, coagulopathy, liver and CNS dysfunctions. Triggers of MAS could be disease activity, infections and medications. Known IL-1 is the key cytokine in pathogenesis of MAS and SJIA, and disease flare associated with increased amounts of different cytokines, especially IL-1β. Many cases of MAS are medically-refractory to traditional doses of cytokine inhibition and may require increased dosing of biologic cytokine blockade. Interleukin-1 (IL-1) is typically a key cytokine in the pathogenesis of sJIA and associated MAS. When MAS occurs in the setting of sJIA treated with IL-1 inhibitors, then increased dosing of IL-1 blockers may be beneficial. This has been shown for anakinra, an IL-1 receptor antagonist, but this drug is currently not available worldwide. Another IL-1 blocker, canakinumbab (CKB), is a monoclonal antibody that blocks IL-1β, but does not also block IL-1α like anakinra. Herein, we describe 2 sJIA patients who developed MAS on standard doses of CKB (4 mg/kg). Both patients received an increased dose of CKB: 150 mg (7.5 and 12.5 mg/kg, respectively) with rapid and complete resolution of MAS. Later the CKB doses was tapered to normal regimen. No side effects or adverse events were noticed during usage of increased CKB doses. Increased dosing of CKB should be considered for CKB-treated sJIA patients who develop MAS on standard dosing.

Published
2014
Full Text
View/download PDF

29. Hypothesis about the protective role of ccr5delta32 mutations in juvenile idiopathic arthritis: fiction or reality?

Author

Masalova Vera Vasilyevna, Santimov Andrey Vyacheslavovich, Egorov Andrey Sergeyevich, Nekhai Sergei, Dubko Margarita Fedorovna, Ammosova Tatyana, Kostik Mikhail Mikhaylovich, Fedorova Elena Vladimirovna, Likhacheva Tatyana Serafimovna, Snegireva Ludmila Stepanovna, Chasnyk Vyacheslav Grigoryevich, Kalashnikova Olga Valeryevna, Grom Alexey Alekseevich, and Avrusin Sergey Lvovich

Subjects
Mutation, education.field_of_study, business.industry, Population, Ethnic group, Arthritis, Disease, medicine.disease_cause, medicine.disease, Chemokine receptor, СИСТЕМНЫЙ ЮВЕНИЛЬНЫЙ ИДИОПАТИЧЕСКИЙ АРТРИТ,SYSTEM ONSET JUVENILE IDIOPATHIC ARTHRITIS,МУТАЦИИ,MUTATION,CCR5DELTA32,ЭТНИЧНОСТЬ,ETHNICITY, Polymorphism (computer science), Macrophage activation syndrome, Immunology, medicine, education, business
Abstract

It is suspected that the prevalence in different ethnic groups of HLA-genotype and of mutation CCR5delta32 - factors which alter adhesion of protein CCR5 - are the causes of different prevalence of juvenile idiopathic arthritis in different ethnic populations. Prerequisites to the fact that the mutation CCR5delta32 may have importance in determining susceptibility to the disease were the observations showing that CCR5 deletion polymorphism reveals a population and geographic diversity in addition to ethnic specificity. But reports on the role of gene deletion in the CCR5 chemokine receptor susceptibility to JIA rather contradictory. 234 DNA samples of patients with systemic JIA (soJIA) were ana-lyzed. The diagnosis was made according to the ILAR criteria. DNA was isolated using QIAamp Mini Kit (QIAGEN) according to the protocol provided. Our results didn’t reveal any differences in prevalence of mutation in patients with soJIA, in patients with soJIA + macrophage activation syndrome and in total population. Our results do not support the idea of protective role of the muta-tion CCR5delta32 against soJIA, which conclusion can be explained also by probable association of soJIA with HLA-genotype or other factors of ethnicity. At the same time, it can be considered as an additional evidence of expediency of soJIA being an original disease different from the rest of JIA group of diseases.

Published
2014
Full Text
View/download PDF

30. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study.

Author

Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Chasnyk, Vyacheslav, Wulffraat, Nico, Palmblad, Karin, Wouters, Carine, I. Brunner, Hermine, Marzan, Katherine, Schneider, Rayfel, Horneff, Gerd, Martini, Alberto, Anton, Jordi, Wei, Xiaoling, Slade, Alan, Ruperto, Nicolino, Abrams, Ken, Emminger, W., Ulbrich, A., and Fodor, S.

Subjects
THERAPEUTIC use of monoclonal antibodies, SUBCUTANEOUS injections, DRUG therapy, METHOTREXATE, MONOCLONAL antibodies, JUVENILE idiopathic arthritis, LOGISTIC regression analysis, RANDOMIZED controlled trials, DISEASE remission, DESCRIPTIVE statistics
Abstract

Objective: To evaluate the efficacy and safety of 2 canakinumab monotherapy tapering regimens in order to maintain complete clinical remission in children with systemic juvenile idiopathic arthritis (JIA). Methods: The study was designed as a 2‐part phase IIIb/IV open‐label, randomized trial. In the first part, patients received 4 mg/kg of canakinumab subcutaneously every 4 weeks and discontinued glucocorticoids and/or methotrexate as appropriate. Patients in whom clinical remission was achieved (inactive disease for at least 24 weeks) with canakinumab monotherapy were entered into the second part of the trial, in which they were randomized 1:1 into 1 of 2 treatment arms. In arm 1, the dose of canakinumab was reduced from 4 mg/kg to 2 mg/kg and then to 1 mg/kg, followed by discontinuation. In arm 2, the 4 mg/kg dose interval was prolonged from every 4 weeks, to every 8 weeks, and then to every 12 weeks, followed by discontinuation. In both arms, canakinumab exposure could be reduced provided systemic JIA remained in clinical remission for 24 weeks with each step. The primary objective was to assess whether >40% of randomized patients in either arm maintained clinical remission of systemic JIA for 24 weeks in the first part of the study. Results: In part 1 of the study, 182 patients were enrolled, with 75 of those patients randomized before entering part 2 of the trial. Among the 75 randomized patients, clinical remission was maintained for 24 weeks in 27 (71%) of 38 patients in arm 1 (2 mg/kg every 4 weeks) and 31 (84%) of 37 patients in arm 2 (4 mg/kg every 8 weeks) (P ≤ 0.0001 for arm 1 versus arm 2 among those meeting the 40% threshold). Overall, 25 (33%) of 75 patients discontinued canakinumab, and clinical remission was maintained for at least 24 weeks in all 25 of these patients. No new safety signals were identified. Conclusion: Reduction of canakinumab exposure may be feasible in patients who have achieved clinical remission of systemic JIA, but consistent interleukin‐1 inhibition appears necessary to maintain this response. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study.

Author

Brunner, Hermine I., Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné‐Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M., Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle‐Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J., and Levy, Jeremy

Subjects
THERAPEUTIC use of monoclonal antibodies, SUBCUTANEOUS injections, CLINICAL trials, COMPARATIVE studies, CONFIDENCE intervals, FEVER, GLUCOCORTICOIDS, MONOCLONAL antibodies, JUVENILE idiopathic arthritis, TREATMENT effectiveness, DISEASE remission, DESCRIPTIVE statistics, ODDS ratio
Abstract

Objective: To evaluate the long‐term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. Methods: At enrollment, patients with active systemic JIA (ages 2 to <20 years) started open‐label canakinumab (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included the adapted American College of Rheumatology (ACR) Pediatric 50/70/90 criteria, the Juvenile Arthritis Disease Activity Score (JADAS), and clinically inactive disease and clinical remission on medication, evaluated by either the JADAS or ACR criteria. Results: Of the 123 patients (70 with fever and 52 without fever [fever status was not reported for 1 patient]), 84 (68.3%) completed the study (median duration 1.8 years). Comparable efficacy (adapted ACR Pediatric 50/70/90/100) was observed by day 15 in both subgroups (60.0%/48.6%/37.1%/24.3% in those with fever and 67.3%/48.1%/34.6%/19.2% in those without fever), and further increased thereafter. By month 6, clinical remission according to the JADAS or the ACR criteria was achieved in 17 (24.3%) and 26 (37.1%), respectively, of patients with fever and 9 (17.3%) and 12 (23.1%), respectively, of patients without fever. Median time to onset of clinical remission according to the JADAS or ACR criteria was 57 and 30 days, respectively, in those with fever, and 58 and 142 days, respectively, in those without fever. An adapted ACR Pediatric 50 response by day 15 was the strongest predictor of achieving clinical remission according to the JADAS (odds ratio [OR] 13 [95% confidence interval (95% CI) 4, 42]; P < 0.0001) or glucocorticoid discontinuation (OR 19 [95% CI 3, 114]; P = 0.002). Of the 71 of 123 patients (57.7%) who received glucocorticoids at study entry, 27 (38.0%) discontinued glucocorticoids and 21 (29.6%) reached a dose of <0.2 mg/kg/day, with no difference between those with and those without fever; 13 patients (10.6%) tolerated a sustained canakinumab dose reduction to 2 mg/kg every 4 weeks. No new safety findings were observed. Conclusion: Canakinumab provided rapid and sustained improvement of active systemic JIA irrespective of the presence of fever at treatment initiation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 2

Author

Alexeeva, Ekaterina I., primary, Dvoryakovskaya, Tatiana M., additional, Nikishina, Irina P., additional, Denisova, Rina V., additional, Podchernyaeva, Nadezhda S., additional, Sukhorukikh, Ol’ga A., additional, Shubina, Lyubov’ S., additional, Chasnyk, Vyacheslav G., additional, and Kostik, Mikhail M., additional

Published
2018
Full Text
View/download PDF

33. ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY

Author

Kostik, Mikhail M., primary, Chikova, Irina A., additional, Isupova, Eugenia A., additional, Likhacheva, Maria N., additional, Likhacheva, Tatyana S., additional, Dubko, Margaruta F., additional, Masalova, Vera V., additional, Snegireva, Ludmila S., additional, Gaidar, Ekaterina V., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2018
Full Text
View/download PDF

34. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

Author

Immuno/reuma patientenzorg, Infection & Immunity, Child Health, Reumatologie patientenzorg, UMC Utrecht, Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G., Panaviene, Violeta Vladislava, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J., Del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D., Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R., Sztajnbok, Flavio, Gilmer, Keith E., Xu, Zhenhua, Leu, Jocelyn H., Kim, Lilianne, Lamberth, Sarah L., Loza, Matthew J., Lovell, Daniel J., Martini, Alberto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), Immuno/reuma patientenzorg, Infection & Immunity, Child Health, Reumatologie patientenzorg, UMC Utrecht, Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G., Panaviene, Violeta Vladislava, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J., Del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D., Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R., Sztajnbok, Flavio, Gilmer, Keith E., Xu, Zhenhua, Leu, Jocelyn H., Kim, Lilianne, Lamberth, Sarah L., Loza, Matthew J., Lovell, Daniel J., Martini, Alberto, and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

Published
2018

35. Multizentrische, doppelblinde, randomisierte Studie von Golimumab bei pädiatrischen Patienten mit aktiver pJIA trotz Methotrexat: Ergebnisse nach 48 Wochen

Author

Brunner, Hermine, Horneff, Gerd, Ruperto, Nicola, Tzaribachev, Nikolay, Wouters, Carine, Chasnyk, Vyacheslav, Cuttica, Ruben, Keltsev, V., Nasonov, Evgeny, Kingsbury, D., Weller-Heinemann, Frank, Lovell, Daniel J., Martini, Alberto, Panaviene, Violeta Vladislava, Abud Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Joos, Rik, Bandeira, Márcia, Silverman, Earl, Van Royen-Kerkhof, Annet, Kim, Lilianne, and Rubio-Perez, Nadina

Subjects
ddc: 610, randomisiert, doppelblind, 610 Medical sciences, Medicine, klinische Remission, ACR30-Ansprechen, Golimumab, juvenile idiopathische Arthritis
Abstract

Einleitung: Beurteilung der Wirksamkeit und Sicherheit von Golimumab (GLM) bei pädiatrischen Patienten (2-17 Jahre) mit aktiver polyartikulärer juveniler idiopathischer Arthritis (pJIA) trotz mindestens 3-monatiger MTX-Therapie. Methoden: GO-KIDS war eine 3-phasige (P1: Wo0-16, P2: Wo16-48,[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016

36. In Children With Systemic Juvenile Idiopathic Arthritis With And Without Fever Canakinumab is Long Term Safe and Efficacious

Author

Horneff, Gerd, Ruperto, Nicola, Brunner, Hermine, Quartier, Pierre, Constantin, Tamas, Alexeeva, Ekaterina, Kone-Paut, Isabelle, Marzan, Katherine, Wulffraat, Nico, Schneider, Rayfel, Padeh, Shai, Chasnyk, Vyacheslav, Wouters, Carine, Kümmerle-Deschner, Jasmin, Kallinich, Tilmann, Lauwerys, Bernard. R., Haddad, Elie, Nasonov, Evgeny, Trachana, Maria, Vougiouka, Olga, Abrams, Ken, Leon, Karolynn, Lheritier, Karine, Martini, Alberto, and Lovell, Daniel J.

Subjects
ddc: 610, fungi, food and beverages, 610 Medical sciences, Medicine
Abstract

Introduction: Rapid and sustained efficacy of canakinumab (CAN) were previously demonstrated in patients with systemic juvenile idiopathic arthritis (SJIA)1. However, little is known about potential differences in response to CAN treatment between pts with vs. without SJIA associated fever. The objective[for full text, please go to the a.m. URL], 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2015

37. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

Author

Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Peng, Lu, Cuttica, Ruben, Keltsev, Vladimir, Xavier, Ricardo M., Calvo, Inmaculada, Nikishina, Irina, Rubio-Pérez, Nadina, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl, Spindler, Alberto, Baildam, Eileen, Gámir, M. Luz, Martin, Alan, Rietschel, Christoph, Siri, Daniel, Smolewska, Elzbieta, Lovell, Daniel, Martini, Alberto, De Benedetti, Fabrizio, Sherrard, T., Johnson, A., Merritt, A., Long, W., Angioloni, Simona, Carenini, Laura, Pallotti, Chiara, Mosci, Eugenia, Garrone, Marco, Gregorini, Irene, Scala, Silvia, Villa, Luca, Silvestri, Giuseppe, Espada, Graciela, Allen, Roger, Chaitow, Jeffrey, Joos, Rik, Wouters, Carine, Knupp, Sheila, Sztajnbok, Flavio, Cabral, David, Houghton, Kristin, Roth, Johannes, Schmeling, Heinrike, Job-Deslandre, Chantal, Jorgensen, Christian, Konepaut, Isabelle, Minden, Kirsten, Weller, Frank, Gerloni, Valeria, Zulian, Francesco, Burgos-Vargas, Ruben, Salazar, Carolina Duarte, Vallejo, Eunice Solis, Calvo, Armando, Chavez, José, Zavaler, Manuel Ferrandiz, Gruenpeter, Anna, Kobusinska, Katarzyna, Sarychev, Alexey, Zholobova, Elena, Ramanan, Athimalaipet, Woo, Patricia, Gedalia, Abraham, Goodman, Steven, Kimura, Yukiko, Onel, Karen, Schikler, Kenneth, and Wouters, Carine

Subjects
Genetics and Molecular Biology (all), Male, DMARDs (biologic), Juvenile Idiopathic Arthritis, Treatment, Adolescent, Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Bronchitis, Cellulitis, Child, Child, Preschool, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Maintenance Chemotherapy, Methotrexate, Pneumonia, Receptors, Interleukin-6, Remission Induction, Treatment Outcome, Rheumatology, Immunology and Allergy, Immunology, Biochemistry, Genetics and Molecular Biology (all), Arthritis, Juvenile, Biochemistry, chemistry.chemical_compound, Monoclonal, Receptors, Medicine, skin and connective tissue diseases, Humanized, Artrite, Connective tissue disease, Rheumatoid arthritis, Combination, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, General Biochemistry, Genetics and Molecular Biology, Antibodies, Tocilizumab, Drug Therapy, Internal medicine, Preschool, Imunossupressores, business.industry, Interleukin-6, Clinical and Epidemiological Research, medicine.disease, Surgery, Método duplo-cego, chemistry, business
Abstract

ObjectiveTo evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).MethodsThis three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) ResultsIn part 1, 188 patients received tocilizumab (ConclusionsTocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis.Trial registration number:NCT00988221.

Published
2014

38. Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis A Multinational, Multicenter Study of 362 Patients

Author

Minoia, Francesca Davi, Sergio Horne, AnnaCarin Demirkaya, Erkan Bovis, Francesca Li, Caifeng Lehmberg, Kai and Weitzman, Sheila Insalaco, Antonella Wouters, Carine Shenoi, Susan Espada, Graciela Ozen, Seza Anton, Jordi and Khubchandani, Raju Russo, Ricardo Pal, Priyankar Kasapcopur, Ozgur Miettunen, Paivi Maritsi, Despoina Merino, Rosa and Shakoory, Bita Alessio, Maria Chasnyk, Vyacheslav Sanner, Helga Gao, Yi-Jin Zeng Huasong Kitoh, Toshiyuki Avcin, Tadej Fischbach, Michel Frosch, Michael Grom, Alexei and Huber, Adam Jelusic, Marija Sawhney, Sujata Uziel, Yosef and Ruperto, Nicolino Martini, Alberto Cron, Randy Q. Ravelli, Angelo Pediat Rheumatology Int Trials Org Childhood Arthrit Rheumatology Res Pediat Rheumatology Collaborative Histiocyte Soc

Subjects
musculoskeletal diseases
Abstract

Objective. To describe the clinical, laboratory, and histopathologic features, current treatment, and outcome of patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA). Methods. In this multinational, multicenter study, pediatric rheumatologists and hemato-oncologists entered patient data collected retrospectively into a web-based database. Results. A total of 362 patients, 22% of whom had MAS at the onset of systemic JIA, were included in the study by 95 investigators from 33 countries. The most frequent clinical manifestations were fever (96%), hepatomegaly (70%), and splenomegaly (58%). Central nervous system dysfunction and hemorrhages were recorded in 35% and 20% of the patients, respectively. Platelet count and liver transaminase, ferritin, lactate dehydrogenase, triglyceride, and D-dimer levels were the sole laboratory biomarkers showing a percentage change of >50% between the pre-MAS visit and MAS onset. Evidence of macrophage hemophagocytosis was found in 60% of the patients who underwent bone marrow aspiration. MAS occurred most frequently in the setting of active underlying disease, in the absence of a specific trigger. Nearly all patients were given corticosteroids, and 61% received cyclosporine. Biologic medications and etoposide were given to 15% and 12% of the patients, respectively. Approximately one-third of the patients required admission to the intensive care unit (ICU), and the mortality rate was 8%. Conclusion. This study provides information on the clinical spectrum and current management of systemic JIA-associated MAS through the analysis of a very large patient sample. MAS remains a serious condition, as a sizeable proportion of patients required admission to the ICU or died.

Published
2014

39. Hepcidin: a promising marker for differential diagnosis of anemia and macrophage activation syndrome in children with juvenile idiopathic arthritis

Author

Dubko Margarita Fedorovna, Fedorova Elena Vladimirovna, Snegireva Ludmila Stepanovna, Masalova Vera Vasilyevna, Egorov Andrey Sergeyevich, Likhacheva Tatyana Serafimovna, Kalashnikova Olga Valeryevna, Chasnyk Vyacheslav Grigoryevich, and Kostik Mikhail Mikhaylovich

Subjects
musculoskeletal diseases, medicine.medical_specialty, biology, medicine.diagnostic_test, business.industry, Anemia, HEPCIDIN,АНЕМИЯ,ANEMIA,СИНДРОМ МАКРОФАГАЛЬНОЙ АКТИВАЦИИ,MACROPHAGE ACTIVATION SYNDROME,ЮВЕНИЛЬНЫЙ ИДИОПАТИЧЕСКИЙ АРТРИТ,JUVENILE RHEUMATOID ARTHRITIS,ГЕПСИДИН, medicine.disease, Ferritin, chemistry.chemical_compound, Endocrinology, Tocilizumab, chemistry, Hepcidin, Total iron-binding capacity, Internal medicine, Macrophage activation syndrome, hemic and lymphatic diseases, Immunology, biology.protein, medicine, business, CD163, Soluble transferrin receptor
Abstract

Hepcidin is a 25-amino acid peptide, which is a key systemic regulator of iron metabolism. As considered, overproduction of hepcidin in the liver is controlled by high levels of proinflammatory cytokines. Is it known that interleukin-6 play a key role in the development of anemia in patients with juvenile idiopathic arthritis (JIA). However, IL-6 blockers itself may provoke the onset of Macrophage Activation Syndrome (MAS), manifesting, particularly, also with anemia. In view of the fact that macrophages involved in MAS express CD163 - a scavenger receptor that binds hemoglobin-haptoglobin complexes - and activate the pathways which are important for adaptation to oxidative stress induced by free iron, we can consider hepcidin as a welcome challenge to predict the development of MAS early in the course of the disease. During the study of 35 patients with JIA treated with biological disease-modifying drugs (tocilizumab and golimumab), direct relations between the level of hemoglobin and hepcidin were not found. However, it was found that the mean corpuscular hemoglobin level is associated with hepcidin concentration in patients with JIA. It was found that concentration of serum hepcidin may be used for early differential diagnosis of anemia and MAS in patients with JIA. High probability of evolution of anemia to MAS was found when concentration of hepcidin was 160 g/L. The following combinations were associated with high probability of evolution of slight anemia to a severe form, but not to MAS: 1. hepcidin >200 ng/mL and ferritin 140 ng/mL and soluble transferrin receptor 140 ng/mL and total iron binding capacity >46 mcmol/L. Misclassification should be assessed during further studies.

Published
2014

40. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Author

Kostik, Mikhail M, primary, Dubko, Margarita F, additional, Masalova, Vera V, additional, Snegireva, Ludmila S, additional, Kornishina, Tatyana L, additional, Chikova, Irina A, additional, Isupova, Eugenia A, additional, Kuchinskaya, Ekaterina M, additional, Glebova, Natalia I, additional, Buchinskaya, Natalia V, additional, Kalashnikova, Olga V, additional, and Chasnyk, Vyacheslav G, additional

Published
2015
Full Text
View/download PDF

42. Identification of the best cut-off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis

Author

Kostik, Mikhail M, primary, Dubko, Margarita, additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, Chikova, Irina, additional, Kornishina, Tatyana, additional, Isupova, Eugenia, additional, Likhacheva, Tatyana, additional, Glebova, Natalia, additional, Kuchinskaya, Ekaterina, additional, Balbotkina, Eugenia, additional, Buchinskaya, Natalia, additional, Kalashnikova, Olga, additional, and Chasnyk, Vyacheslav, additional

Published
2014
Full Text
View/download PDF

43. O53. Efficacy and Safety of Tocilizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: 2 Year Data from Cherish

Author

Baildam, Eileen, primary, Ramanan, Athimalaipet, additional, Woo, Patricia, additional, Brunner, Hermine, additional, Ruperto, Nicola, additional, Zuber, Zbyszek, additional, Cuttica, Rubén J., additional, Xavier, Ricardo, additional, Penades, Inmaculada Calvo, additional, Rubio-Perez, Nadina, additional, Alexeeva, Ekaterina, additional, Chasnyk, Vyacheslav, additional, Chavez, Jose, additional, Horneff, Gerd, additional, Opoka-Winiarska, Violetta, additional, Quartier, Pierre, additional, Spindler, Alberto, additional, Keane, Caroline, additional, Bharucha, Kamal, additional, Wang, Jianmei, additional, Lovell, Daniel J., additional, Martini, Alberto, additional, and De Benedetti, Fabrizio, additional

Published
2014
Full Text
View/download PDF

44. A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH

Author

Brunner, Hermine, primary, Ruperto, Nicolino, additional, Zuber, Zbigniew, additional, Cuttica, Rubén J., additional, Xavier, Ricardo, additional, Calvo, Inmaculada, additional, Rubio, Nadina, additional, Alekseeva, Ekaterina, additional, Chasnyk, Vyacheslav, additional, Chavez, Jose, additional, Horneff, Gerd, additional, Opoka-Winiarska, Violetta, additional, Quartier, Pierre, additional, Spindler, Alberto, additional, Keane, Caroline, additional, Bharucha, Kamal N., additional, Wang, Jianmei, additional, Lovell, Daniel J., additional, Martini, Alberto, additional, and De Benedetti, Fabrizio, additional

Published
2014
Full Text
View/download PDF

45. A98: Rescue Treatment by Increased Doses of IL-1 Inhibitors for Macrophage Activation Syndrome in Children With Systemic Juvenile Idiopathic Arthritis

Author

Kostik, Mikhail, primary, Snegireva, Ludmila, additional, Dubko, Margarita, additional, Masalova, Vera, additional, Likhacheva, Tatyana, additional, Kornishina, Tatyana, additional, Chikova, Irina, additional, Buchinskaya, Natalia, additional, Kalashnikova, Olga, additional, and Chasnyk, Vyacheslav, additional

Published
2014
Full Text
View/download PDF

46. A87: Different Tocilizumab Therapeutic Protocols and Possibility Achieving Tocilizumab-Off Remission in Systemic Juvenile Idiopathic Arthritis

Author

Kostik, Mikhail, primary, Dubko, Margarita, additional, Snegireva, Ludmila, additional, Masalova, Vera, additional, Kornishina, Tatyana, additional, Likhacheva, Tatyana, additional, Chikova, Irina, additional, Isupova, Eugenia, additional, Kuchinskaya, Ekaterina, additional, Glebova, Natalya, additional, Kalashnikova, Olga, additional, and Chasnyk, Vyacheslav, additional

Published
2014
Full Text
View/download PDF

47. A130: Is the CCR5-delta32 Mutation Protective Against Systemic-Onset Juvenile Idiopathic Arthritis?

Author

Chasnyk, Vyacheslav, primary, Fedorova, Elena, additional, Egorov, Andrey, additional, Ammosova, Tatiana, additional, Nekhai, Sergei, additional, Kostik, Mikhail, additional, Santimov, Andrei, additional, Dubko, Margarita, additional, Kalashnikova, Olga, additional, Masalova, Vera, additional, Likhacheva, Tatyana, additional, Snegireva, Ludmila, additional, and Grom, Alexei, additional

Published
2014
Full Text
View/download PDF

49. A128: Hierarchical Clustering Methodology for Exploration of Proteomic Profile in Tears: Seeking for Markers of Uveitis Associated With Juvenile Idiopathic Arthritis

Author

Nekhai, Sergei, primary, Hynes, Alla, additional, Ammosova, Tatiana, additional, Obukhov, Yuri, additional, Gaidar, Ekaterina, additional, Kononov, Anatoly, additional, Dubko, Margarita, additional, Nikitina, Tatiana, additional, Serogodskaia, Elena, additional, Kostik, Mikhail, additional, Kalashnikova, Olga, additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, and Chasnyk, Vyacheslav, additional

Published
2014
Full Text
View/download PDF

50. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria

Author

Ozen, Seza, Pistorio, Angela, Iusan, Silvia M, Bakkaloglu, Aysin, Herlin, Troels, Brik, Riva, Buoncompagni, Antonella, Lazar, Calin, Bilge, Ilmay, Uziel, Yosef, Rigante, Donato, Cantarini, Luca, Hilario, Maria Odete, Silva, Clovis A, Alegria, Mauricio, Norambuena, Ximena, Belot, Alexandre, Berkun, Yackov, Estrella, Amparo Ibanez, Olivieri, Alma Nunzia, Alpigiani, Maria Giannina, Rumba, Ingrida, Sztajnbok, Flavio, Tambic-Bukovac, Lana, Breda, Luciana, Al-Mayouf, Sulaiman, Mihaylova, Dimitrina, Chasnyk, Vyacheslav, Sengler, Claudia, Klein-Gitelman, Maria, Djeddi, Djamal, Nuno, Laura, Pruunsild, Chris, Brunner, Jurgen, Kondi, Anuela, Pagava, Karaman, Pederzoli, Silvia, Martini, Alberto, Ruperto, Nicolino, Nielsen, Susan Mary, Ozen, Seza, Pistorio, Angela, Iusan, Silvia M, Bakkaloglu, Aysin, Herlin, Troels, Brik, Riva, Buoncompagni, Antonella, Lazar, Calin, Bilge, Ilmay, Uziel, Yosef, Rigante, Donato, Cantarini, Luca, Hilario, Maria Odete, Silva, Clovis A, Alegria, Mauricio, Norambuena, Ximena, Belot, Alexandre, Berkun, Yackov, Estrella, Amparo Ibanez, Olivieri, Alma Nunzia, Alpigiani, Maria Giannina, Rumba, Ingrida, Sztajnbok, Flavio, Tambic-Bukovac, Lana, Breda, Luciana, Al-Mayouf, Sulaiman, Mihaylova, Dimitrina, Chasnyk, Vyacheslav, Sengler, Claudia, Klein-Gitelman, Maria, Djeddi, Djamal, Nuno, Laura, Pruunsild, Chris, Brunner, Jurgen, Kondi, Anuela, Pagava, Karaman, Pederzoli, Silvia, Martini, Alberto, Ruperto, Nicolino, and Nielsen, Susan Mary

Abstract

To validate the previously proposed classification criteria for Henoch-Schönlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) and c-Takayasu arteritis (c-TA).

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results